Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2420 in Combination With Somatostatin Analogs in Adult Participants With Acromegaly
NCT07037420Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Oct 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of AZP-3813 in acromegaly, sponsored by Alexion Pharmaceuticals. Started Oct 2025; status: terminated.
02
Drugs
AZP-3813
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT07037420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07037420.